PL1638591T3 - Agoniści SLRP klasy III do stosowania w ograniczeniu tworzenia naczyń krwionośnych - Google Patents

Agoniści SLRP klasy III do stosowania w ograniczeniu tworzenia naczyń krwionośnych

Info

Publication number
PL1638591T3
PL1638591T3 PL04735259T PL04735259T PL1638591T3 PL 1638591 T3 PL1638591 T3 PL 1638591T3 PL 04735259 T PL04735259 T PL 04735259T PL 04735259 T PL04735259 T PL 04735259T PL 1638591 T3 PL1638591 T3 PL 1638591T3
Authority
PL
Poland
Prior art keywords
agonists
reduction
blood vessel
class iii
vessel formation
Prior art date
Application number
PL04735259T
Other languages
English (en)
Inventor
Paul N Bishop
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312292A external-priority patent/GB0312292D0/en
Priority claimed from GB0400547A external-priority patent/GB0400547D0/en
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of PL1638591T3 publication Critical patent/PL1638591T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04735259T 2003-05-29 2004-05-28 Agoniści SLRP klasy III do stosowania w ograniczeniu tworzenia naczyń krwionośnych PL1638591T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0312292A GB0312292D0 (en) 2003-05-29 2003-05-29 Treatment of blood vessels
GB0400547A GB0400547D0 (en) 2004-01-12 2004-01-12 Treatment of blood vessels
PCT/GB2004/002269 WO2004105784A1 (en) 2003-05-29 2004-05-28 Class iii slrp agonists for the reduction of blood vessel formation
EP04735259A EP1638591B1 (en) 2003-05-29 2004-05-28 Class iii slrp agonists for the reduction of blood vessel formation

Publications (1)

Publication Number Publication Date
PL1638591T3 true PL1638591T3 (pl) 2013-10-31

Family

ID=33492244

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04735259T PL1638591T3 (pl) 2003-05-29 2004-05-28 Agoniści SLRP klasy III do stosowania w ograniczeniu tworzenia naczyń krwionośnych

Country Status (8)

Country Link
US (2) US7358224B2 (pl)
EP (1) EP1638591B1 (pl)
JP (1) JP4808623B2 (pl)
DK (1) DK1638591T3 (pl)
ES (1) ES2408656T3 (pl)
PL (1) PL1638591T3 (pl)
PT (1) PT1638591E (pl)
WO (1) WO2004105784A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358224B2 (en) * 2003-05-29 2008-04-15 The University Of Manchester Class III SLRP agonists for the reduction of blood vessel formation
GB0423273D0 (en) * 2004-10-20 2004-11-24 Univ Manchester Treatment of cancer
GB0724832D0 (en) * 2007-12-20 2008-01-30 Univ Manchester Proteins and nucleic acids
ES2512018T3 (es) 2009-07-27 2014-10-23 F. Hoffmann-La Roche Ag Utilización de mimecán en la evaluación de la insuficiencia cardiaca
WO2011069046A1 (en) * 2009-12-04 2011-06-09 Euclid Systems Corporation Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema
CN102188694B (zh) * 2010-03-11 2015-05-06 上海交通大学医学院附属瑞金医院 骨生成诱导因子的用途
EP3115784A1 (en) * 2015-07-10 2017-01-11 Koss, Michael Janusz Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases
WO2017083925A1 (en) * 2015-11-19 2017-05-26 Garvan Institute Of Medical Research Compounds and methods for treating metabolic disorders
CN121568705A (zh) * 2023-06-13 2026-02-24 格罗宁根大学 作为肺组织再生剂的骨甘氨酸

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
DE4445630A1 (de) 1994-12-21 1996-06-27 Forssmann Wolf Georg Humane zirkulierende Peptidfragmente 20-92 und 23-74 des Precursor des Osteoinduktiven Faktors kurz: OIF-20-92 und OIF 23-74
NZ320006A (en) * 1995-10-23 2001-12-21 Meditech Res Ltd An adjuvant composition comprising hyaluronic acid for gene therapy either in the sense or antisense direction
EP0928203B1 (en) * 1996-09-24 2006-10-25 Merck & Co., Inc. Compounds for the inhibition of angiogenesis by gene therapy
WO1998024466A1 (en) 1996-12-05 1998-06-11 Alcon Laboratories, Inc. THE USE OF INHIBITORS OF TGF-β'S FUNCTIONS TO AMELIORATE OCULAR PATHOLOGY
US6413931B1 (en) 1999-05-10 2002-07-02 The Texas A&M University System Peptide inhibitor of fibrinogen blood clotting
JP4786095B2 (ja) * 1999-09-15 2011-10-05 ユークリッド システムズ コーポレイション 角膜矯正レンズ装着中または装着後の角膜組織を安定化するための組成物
AU7603800A (en) * 1999-09-24 2001-04-24 Human Genome Sciences, Inc. 32 human secreted proteins
US7304137B2 (en) * 2001-12-13 2007-12-04 The Texas A & M University System Nucleotide and amino acid sequences of asporins
US7358224B2 (en) 2003-05-29 2008-04-15 The University Of Manchester Class III SLRP agonists for the reduction of blood vessel formation
GB0423273D0 (en) 2004-10-20 2004-11-24 Univ Manchester Treatment of cancer

Also Published As

Publication number Publication date
DK1638591T3 (da) 2013-06-03
EP1638591B1 (en) 2013-03-13
US20090130192A1 (en) 2009-05-21
ES2408656T3 (es) 2013-06-21
PT1638591E (pt) 2013-05-22
JP2007502855A (ja) 2007-02-15
WO2004105784A1 (en) 2004-12-09
US7910567B2 (en) 2011-03-22
US7358224B2 (en) 2008-04-15
US20070021334A1 (en) 2007-01-25
EP1638591A1 (en) 2006-03-29
JP4808623B2 (ja) 2011-11-02

Similar Documents

Publication Publication Date Title
GB2397500B (en) Cartridge for the preparation of beverages
EP1795457A4 (en) CONTAINER FOR MIXING A LIQUID INTO TWO PARTS OR SIMILAR
SG134996A1 (en) Extended semi-submersible vessel
IL166171A0 (en) Blood clot-targeted nanoparticles
IL173456A0 (en) Process for the preparation of 4-amino-3-quinolinecarbonitriles
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
PL1838301T3 (pl) Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe
GB2397496B (en) Cartridge for the preparation of beverages
ZA200407609B (en) Use of vitamin d compounds
GB2392441B (en) Electrolytic activation of fluids
GB2413471B (en) Tomography of curved surfaces
AU2003272198A1 (en) Storage of blood
TWI347945B (en) Process for the preparation of thiazolopyrimidines
GB0419199D0 (en) Methods of diagnosis
IL161897A0 (en) Process for the preparation of cephalexin
GB0420873D0 (en) Methods of diagnosis
ZA200408616B (en) The determination of medical aid options
ZA200509495B (en) Process for the preparation of nicotinaldehydes
IL158442A0 (en) Blood vessels wall imaging catheter
GB0316139D0 (en) Use of fluoroquinolone antibiotics for the treatment of plague
HU0300255D0 (en) Process for the preparation of 2-phenyl-4-methyl-1-tosil-piperazine
HK1077849A (en) Diagnosis of chronic rejection
GB0312292D0 (en) Treatment of blood vessels
AU2003905318A0 (en) Combination vessel
GB0224232D0 (en) Use of fluoroquinolone antibodies for the treatment of anthrax